Navigation Links
New Pneumococcal Vaccine Approach Successful in Early Tests
Date:2/16/2011

BOSTON, Feb. 16, 2011 /PRNewswire-USNewswire/ -- Pneumococcus (Streptococcus pneumoniae) accounts for as much as 11 percent of mortality in young children worldwide. While successful vaccines like Prevnar® exist, they are expensive and only work against specific pneumococcal strains, with the risk of becoming less effective as new strains emerge. Through a novel discovery approach, researchers at Children's Hospital Boston and Genocea Biosciences, Inc., in collaboration with the international nonprofit organization PATH, developed a new vaccine candidate that is potentially cheaper and able to protect against any pneumococcal strain.

Tested in mice, the protein-based vaccine successfully inhibited S. pneumoniae from establishing a foothold in the body, the researchers report in the February 17 issue of Cell Host & Microbe.

The current multivalent conjugate pneumococcal vaccines work by inducing people to make antibodies against the sugars on the bacterium's outer capsule. The antibodies then help fight off development of disease after the bacteria have colonized the body. But these vaccines are complex to manufacture, requiring separate individual components for sugars produced by multiple pneumococcal strains. Since pneumococci can make more than 90 different types of sugars, the vaccines may become less effective over time.

The new protein-based vaccine takes a different approach. Based on close to a decade of research at Children's Hospital Boston and utilizing Genocea's novel vaccine discovery technology developed at Harvard Medical School, it stimulates a group of cells in the body known as TH17 cells. These cells provide natural immunity to pneumococcal infection by clearing the bacteria from the surfaces of the upper respiratory tract where infection starts.

Six years ago, Children's Richard Malley, M.
'/>"/>

SOURCE Children's Hospital Boston
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
2. Cyprus and Ireland Add Wyeths 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
3. Reportlinker Adds Vaccine Technologies and Global Markets
4. Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors
5. NOVAVAX and University of Massachusetts Medical School Publish Preclinical Safety and Efficacy Study of a Respiratory Syncytial Virus (RSV) Virus-like Particle (VLP) Vaccine Candidate
6. Vaccinex, Inc. Awarded Three Qualifying Therapeutic Discovery Project (QTDP) Grants Under the Patient Protection and Affordable Care Act of 2010 (PPACA)
7. Medicago Receives Regulatory Approval and Commences Phase II Clinical Testing of its Avian Influenza Vaccine
8. Paragon Bioservices Awarded $4.99 Million U.S. Army Contract to Assist with Ebola Vaccine Development
9. Reportlinker Adds Triple Analysis: Lymphoma, Cancer Vaccines and Antibodies
10. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
11. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... There’s a new treatment option for excessive menstrual ... available new FDA approved system in the last 14 years, and the only endometrial ... (zero bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and the ...
(Date:8/30/2015)... CHERTSEY , England , August ... Kampagne beendet die 51-jährige Wartezeit   einer Frau   ... und Frauen im Alter von 7-90   ... Programm soll 1200 Frauen behandeln und ...     , Astellas gab heute ...
(Date:8/28/2015)... According to a new market ... Systems, Thawing Equipment, Alarms), by Biospecimen (Human Tissue, Stem ... User - Global Forecast to 2020", published by MarketsandMarkets, ... 3,731.03 Million by 2020 from USD 2,150.48 Million in ... and 2020. Browse 74 Tables and ...
(Date:8/28/2015)... ... 28, 2015 , ... Pittcon is pleased to announce that ... on chemical spectroscopic imaging at JASIS 2015 (Japan Analytical & Scientific Instruments Show) ... scientific instruments show which will be held at International Conference Hall in Makuhari ...
Breaking Biology Technology:U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5Biopreservation Market Worth 3,731.03 Million USD by 2020 2Biopreservation Market Worth 3,731.03 Million USD by 2020 3Biopreservation Market Worth 3,731.03 Million USD by 2020 4Biopreservation Market Worth 3,731.03 Million USD by 2020 5U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 2U.S. Symposium on Imaging Organized by Pittcon’s Program Chairman Chuck Gardner 3
... 2, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... pharmaceutical and biotechnology research and development outsourcing company, today ... for the fourth quarter and full year 2010 ended ... host a conference call to discuss the results at ...
... – EMD Serono, Inc., an affiliate of Merck ... a complete response letter (CRL) from the U.S. ... drug application (NDA) for Cladribine Tablets, EMD Serono,s ... therapy for relapsing-remitting multiple sclerosis (MS). ...
... Communications , the team have created a microscope which shatters ... beating the diffraction limit of light. Previously, the standard ... 0.001 millimetres clearly. But now, by combining an ... the Manchester researchers can see 20 times smaller 50 ...
Cached Biology Technology:ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011 2EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 2EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 3EMD Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application 4Microscope could 'solve the cause of viruses' 2
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Saudi Arabia Biomedical Sensors market is estimated at $0.23 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015  Sarcos ... today it will unveil its "Guardian S" snake robot, ... National Tactical Officers Association Conference on August 30 in ... is the first-ever commercially available energetically autonomous snake robot, ... in-field trials and is protected by more than 50 ...
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
Breaking Biology News(10 mins):Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
... scientists at the Broad Institute of MIT and Harvard announced ... that can connect human diseases with potential drugs to treat ... human cells. Called the "Connectivity Map," the new tool and ... Science and in separate publications in the September 28 immediate ...
... your way through an unfamiliar neighborhood to a friend's ... is adept at adapting. It can make decisions based ... new information. , The nature of such sophisticated decision ... high-level processing, has been "poorly studied and little understood," ...
... sequence of a 5-million-year-old retrovirus and shown that it is ... ancestor of a large family of mobile DNA elements, some ... study, which is the first to generate an infectious retrovirus ... a breakthrough for the field of retrovirus research. The ...
Cached Biology News:Genetic 'roadmap' charts links between drugs and human disease 2Genetic 'roadmap' charts links between drugs and human disease 3Where we change our mind 2Scientists resuscitate a 5 million-year-old retrovirus 2